Kansas Must Plan to End Tobacco SalesUniversity of Kansas Cancer Center
The University of Kansas Cancer Center joins 148 organizations from around the world in this public health appeal
The University of Kansas Cancer Center has partnered with 70 other National Cancer Institute (NCI)-designated cancer centers and partner organizations to issue a joint statement urging the nation’s physicians, parents and young adults to get the human papillomavirus (HPV) vaccination back on track.
Nearly 10 million cancer screenings in the U.S. failed to happen because of the COVID-19 pandemic, according to a study published in JAMA Oncology, a publication of the American Medical Association.
Carol Fabian, MD, FASCO, a nationally recognized medical oncologist and breast cancer researcher, has been named a Fellow of the American Society of Clinical Oncology (FASCO).
The University of Kansas Cancer Center is the first and only site in the region to offer CAR T-cell therapy to treat multiple myeloma, a type of blood cancer that affects about 30,000 people each year.
The University of Kansas Cancer Center is part of a nationwide effort to resume appropriate cancer screening and treatment to prevent excess deaths.
Researchers from The University of Kansas Cancer Center are involved in the presentation of nearly 50 research studies at the 62nd American Society of Hematology (ASH) Annual Meeting.
Men with cancer and COVID-19 may be at significantly higher risk for severe symptoms and even death as compared to females fighting both, a University of Kansas Cancer Center research team has found.
Scientists and medical professionals have long debated whether pod e-cigarettes are a safer alternative to traditional cigarettes. A new study provides some insight.
In one year, The University of Kansas Cancer Center will submit its application to renew its prestigious National Cancer Institute (NCI) designation in the hopes of attaining “comprehensive” status, the NCI’s highest ranking.
The University of Kansas Cancer Center’s status as a community site of the National Cancer Institute’s Community Oncology Research Program has been renewed after exceeding clinical trial accrual goals by more than 22% in its first year.
The University of Kansas Medical Center announced today a trial exploring a drug intended to fight the cytokine storm common in COVID-19.
Dr. Chen joins a group of just 19 physicians and medical physicists who are recognized this year for their contributions to the field of radiation oncology.
The University of Kansas Cancer Center is helping fight the pandemic in numerous ways.
Ronald Chen, MD, MPH, has been named a Fellow of the American Society of Clinical Oncology (FASCO) in honor of his extraordinary volunteer service, dedication and commitment to ASCO.
KU Medical Center is one of 60 sites across the nation that will be participating in this clinical trial, led by the Duke Clinical Research Institute.
The University of Kansas Cancer Center will receive an additional $5 million from the state budget for the KU Cancer Center Research Fund.
The University of Kansas Cancer Center has partnered with Fox4 and the Kansas City Kansas School district to host a town hall on vaping at Sumner Academy February 27.
The International Society of Gastrointestinal Oncology (ISGIO), a not-for-profit global educational organization committed to GI oncology, announces that Weijing Sun, MD, FACP, has been elected the society’s next leader.
First patient enrolled at The University of Kansas Cancer Center in expansion cohort study characterizing the safety, pharmacokinetics and pharmacodynamics of fosciclopirox in bladder cancer patients
Ronald Chen, MD, MPH, has been named the Brandmeyer Chair and Professor of Radiation Oncology at the University of Kansas School of Medicine, clinical service chief at The University of Kansas Health System and associate director for Health Equity at The University of Kansas Cancer Center.
The University of Kansas Cancer Center and Midwest Cancer Alliance have been awarded a grant to expand the reach of cancer clinical trials to Kansas’ rural communities.
Clinical health psychology fellowship emphasizes psychological care for people with cancer.
Researchers from The University of Kansas Cancer Center has received a five-year, $2.25 million grant from the National Cancer Institute to study why there are survival rate disparities in rural parts of Kansas, and how to improve them.
A select group of early-career investigators has been selected to be a part of the University of Kansas Medical Center’s $11.5 million precision medicine-focused federal grant.
A research team has been awarded a five-year, $1.8 million grant from the NIH to study chronic inflammation of the liver, a major factor in the development of liver cancer.
A new program seeks to improve community oncology providers’ knowledge of genetic testing in breast cancer patients, as well as provide tools to allow genetic counseling and testing to be incorporated in their clinical practice.
A literature review seeks to summarize the metastatic research landscape and identify the distinguishing features of metastasis. This is the first paper that attempts to define the process in terms of core hallmarks.
A team led by Andrew Godwin, PhD, deputy director of The University of Kansas Cancer Center and director of molecular oncology in the department of Pathology and Laboratory Medicine, has been awarded a five-year, $11.4 million National Institutes of Health phase I Centers for Biomedical Research Excellence (COBRE) grant to establish the Kansas Institute for Precision Medicine at the University of Kansas Medical Center.
The University of Kansas Cancer Center is one of the latest major cancer research institutions to join The Leukemia & Lymphoma Society’s (LLS) Beat AML Master Clinical Trial, a paradigm-shifting collaboration to bring precision medicine to patients with acute myeloid leukemia.
A preclinical study has identified a region of the human genome, called a super-enhancer, as a novel target for a pancreatic cancer subtype.
A new, first-of-its kind project from researchers at The University of Kansas Cancer Center aims to boost participation in urologic cancer clinical trials by partnering with community urologists.
A new ultrasensitive diagnostic device invented by researchers at the University of Kansas, The University of Kansas Cancer Center and KU Medical Center could allow doctors to detect cancer quickly from a droplet of blood or plasma, leading to timelier interventions and better outcomes for patients.
Prateek Sharma, MD, gastroenterologist and member of The University of Kansas Cancer Center, has been named president of The International Society for Diseases of the Esophagus (ISDE). The ISDE is a multidisciplinary international organization comprised of approximately 1,000 esophageal disease experts.
Dineo Khabele, MD, director of The University of Kansas Cancer Center’s gynecologic oncology division, has been elected a new member to the American Society for Clinical Investigation (ASCI) for 2019.
Steven Soper, PhD, member of The University of Kansas Cancer Center, was elected to the American Institute for Medical and Biomedical Engineering (AIMBE) College of Fellows.
The University of Kansas Cancer Center and the the Midwest Cancer Alliance co-hosted an introductory training workshop for individuals who want to learn more about KU Cancer Center’s patient research advocacy program, PIVOT
Researchers work with African American and American Indian communities to identify effective tobacco cessation strategies
Researchers at The University of Kansas Cancer Center have launched a clinical trial that eliminates radiation from the treatment protocol for an invasive type of breast cancer that accounts for one-fifth of all breast cancer patients.
Researchers at The University of Kansas Cancer Center have received a five-year National Institutes of Health R0-1 grant to compare and evaluate the efficacy of optimized versus non-optimized tobacco cessation approaches for African American smokers.
Researchers at The University of Kansas Cancer Center have discovered a therapy combination that may be helpful in the treatment of certain types of ovarian cancer.